Cargando…
Human islet amyloid polypeptide: A therapeutic target for the management of type 2 diabetes mellitus
Type 2 diabetes mellitus (T2DM) and other metabolic disorders are often silent and go unnoticed in patients because of the lack of suitable prognostic and diagnostic markers. The current therapeutic regimens available for managing T2DM do not reverse diabetes; instead, they delay the progression of...
Autores principales: | Roham, Pratiksha H., Save, Shreyada N., Sharma, Shilpy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Xi'an Jiaotong University
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463490/ https://www.ncbi.nlm.nih.gov/pubmed/36105173 http://dx.doi.org/10.1016/j.jpha.2022.04.001 |
Ejemplares similares
-
The potential role of human islet amyloid polypeptide in type 2 diabetes mellitus and Alzheimer’s diseases
por: Alrouji, Mohammed, et al.
Publicado: (2023) -
Molecular Structure, Membrane Interactions, and Toxicity of the Islet Amyloid Polypeptide in Type 2 Diabetes Mellitus
por: Caillon, Lucie, et al.
Publicado: (2016) -
Causative factors for formation of toxic islet amyloid polypeptide oligomer in type 2 diabetes mellitus
por: Jeong, Hye Rin, et al.
Publicado: (2015) -
High Plasma Levels of Islet Amyloid Polypeptide in Young with New-Onset of Type 1 Diabetes Mellitus
por: Paulsson, Johan F., et al.
Publicado: (2014) -
Importance of Aggregated Islet Amyloid Polypeptide for the Progressive Beta-Cell Failure in Type 2 Diabetes and in Transplanted Human Islets
por: Westermark, Gunilla T., et al.
Publicado: (2008)